Skip to main content

What the FDA labels say about taking them together

Fentanyl and palbociclib

Palbociclib's FDA label of July 2, 2026 names fentanyl in its drug interactions section; the fentanyl labels PlainMeds reads (2) do not name palbociclib. The palbociclib label: “The dose of the sensitive CYP3A substrate with a narrow therapeutic index may need to be reduced, as IBRANCE may increase its exposure.”

Check it at the source: the fentanyl FDA label on DailyMed (effective March 6, 2026, Hikma Pharmaceuticals USA Inc.); the palbociclib FDA label on DailyMed (effective July 2, 2026, Pfizer Laboratories Div Pfizer Inc).

What does the fentanyl label say about palbociclib?

Fentanyl's label (effective March 6, 2026) and its 1 other brand-application label do not name palbociclib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Fentanyl Citrate), Hikma Pharmaceuticals USA Inc., effective March 6, 2026 (SPL set ce5db1c2-feb1-4ad2-847a-d02e865bd47e), via openFDA; the full label on DailyMed

What does the palbociclib label say about fentanyl?

Palbociclib label, drug interactions

The dose of the sensitive CYP3A substrate with a narrow therapeutic index (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus) may need to be reduced, as IBRANCE may increase its exposure [see Clinical Pharmacology (12.3) ].

Source: FDA drug label (Ibrance), Pfizer Laboratories Div Pfizer Inc, effective July 2, 2026 (SPL set fecbdd7d-b729-41b5-9872-231b8fe104ce), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

6Fentanyl generic labelers
0Palbociclib generic labelers
FentanylPalbociclib
Labeled forPainBreast cancer
Boxed warningYesNo
Pharmacy cost (NADAC)$1.79 per mL 100 mcg/2 mL vialn/a
Shortage nowIn shortageA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?